Regulatory issues in developing new HIV protease inhibitors: risks and benefits.
Saved in:
| Title: | Regulatory issues in developing new HIV protease inhibitors: risks and benefits. |
|---|---|
| Authors: | Struble KA; Office of New Drugs, Office of Antimicrobial Products, Division of Antiviral Products, US Food and Drug Administration, USA. Kimberly.struble@fda.hhs.gov, Chan-Tack KM, Soon GG |
| Source: | Current opinion in HIV and AIDS [Curr Opin HIV AIDS] 2008 Nov; Vol. 3 (6), pp. 676-80. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 101264945 Publication Model: Print Cited Medium: Internet ISSN: 1746-6318 (Electronic) Linking ISSN: 1746630X NLM ISO Abbreviation: Curr Opin HIV AIDS Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
